Cotización Biomea Fusion - BMEA

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

6.45

Postura de Compra

6.43

Postura de Venta

6.46

Volume Operado de la Acción

255,283

6.0919 Rango del Día 6.50

3.61 Rango de 52 semanas 22.74

Capitalización de Mercado [m]

233.74M

Precio Anterior

6.28

Precio de Apertura

6.3699

Hora

6.445

Última hora de negociación

13:28:43

Volumen financiero

US$ 1,605,104

Precio Promedio Ponderado

6.2875

Volumen promedio (3 m)

796,127

Acciones en circulación

36,238,687

Rendimiento del Dividendo

Ratio Precio/Utilidad

-1.99

Beneficio por acción (BPA)

-3.24

turnover

Beneficio neto

-117.26M

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.biomeafusion.com

Sede

Wilmington, Delaware, USA

Fundado

Biomea Fusion Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BMEA. The last closing price for Biomea Fusion was US$6.28. Over the last year, Biomea Fusion shares have traded in a share price range of US$ 3.61 to US$ 22.74.

Biomea Fusion currently has 36,238,687 shares in issue. The market capitalisation of Biomea Fusion is US$227.58 million. Biomea Fusion has a price to earnings ratio (PE ratio) of -1.99.

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type 2 Diabetes Patients Characterized by Insulin Deficiency 32 patients from the 100mg and...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...

Form 8-K - Current report

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

U.S. Food and Drug Administration (FDA) lifted Clinical Hold on COVALENT-111 (Type 2 Diabetes) & COVALENT-112 (Type 1 Diabetes) trialsCOVALENT-111 Phase 2b 26-week topline data of the dose...

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 R

REDWOOD CITY, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

BMF-219 is an investigational oral covalent menin inhibitor developed to regenerate insulin-producing beta cells Two trial-in-progress oral presentations to feature Phase II study design of oral...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.63	-8.89830508475	7.08	7.5	6.04	671189	6.54992475	CS
4	-4.88	-43.0714916152	11.33	12.85	6.04	816660	8.80971331	CS
12	-1.59	-19.776119403	8.04	13.07	6.04	796127	9.33651347	CS
26	-6.03	-48.3173076923	12.48	13.07	3.61	1058917	7.09435356	CS
52	-3.69	-36.3905325444	10.14	22.74	3.61	1126717	11.24451903	CS
156	-4.53	-41.2568306011	10.98	43.69	2.84	617336	15.16534554	CS
260	-13.55	-67.75	20	43.69	2.84	535418	15.14053387	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
CRNCCerence Inc	US$ 6.1727 (118.89%)	64.35M
WORXSCWorx Corporation	US$ 2.01 (105.10%)	130.13M
SPAISafe Pro Group Inc	US$ 4.589 (43.41%)	41.46M
INVZWInnoviz Technologies Ltd	US$ 0.07 (37.86%)	6.41k
ARQQArqit Quantum Inc	US$ 9.92 (35.15%)	635.49k
SKKSKK Holdings Limited	US$ 0.80 (-82.46%)	23.72M
WCTWellchange Holdings Company Limited	US$ 1.00 (-69.88%)	1.78M
TMTCTMT Acquisition Corporation	US$ 2.375 (-63.12%)	316.51k
GLXGGalaxy Payroll Group Ltd	US$ 1.7062 (-56.36%)	2.18M
TMTCUTMT Acquisition Corporation	US$ 3.20 (-52.10%)	11.54k
CDTConduit Pharmaceuticals Inc	US$ 0.1109 (20.15%)	554.38M
NVDANVIDIA Corporation	US$ 147.13 (0.85%)	315.15M
ELABElevai Labs Inc	US$ 0.0204 (-4.67%)	206.05M
AKTSAkoustis Technologies Inc	US$ 0.101 (15.96%)	199.04M
WORXSCWorx Corporation	US$ 2.01 (105.10%)	130.13M